cardonilizumab combined with renvastinib

Phase 2Small molecule

cardonilizumab combined with renvastinib is one of 44 small molecule programs targeting Renal Cell Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Renal Cell CarcinomaActive, not recruiting

Renal Cell CarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

363 competitors in Renal Cell Carcinoma

#DrugCompanyPhaseTrials

Cabometyx

Bristol-Myers Squibb

Phase 3

31 2

Nexavar

Bayer

Phase 3

23 3

Lenvima

Eisai

Phase 3

21 4

Inlyta

PPrism Pharmaceuticals

Phase 3

27 5

Tecentriq

Roche

Phase 3

8 6

Welireg

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

18 7

Imjudo

AstraZeneca

Phase 3

3 8

Imfinzi

AstraZeneca

Phase 3

2 9

TKI258

Novartis

Phase 3

1 10

Roferon-a

Roche

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Not yet recruiting

Renal Cell Carcinoma

NCT06574412

Clinical

Trials by Indication[1]

Renal Cell Carcinoma1 trial

Cardenilimab Combined With Lenvatinib in Patients With Perioperative Resectable Clear Cell Renal Cell Carcinoma.

Not yet recruiting·TThe First Hospital of Jilin University·Phase 2·NCT06574412·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for cardonilizumab combined with renvastinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — cardonilizumab combined with renvastinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for cardonilizumab combined with renvastinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The First Hospital of Jilin University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TThe First Hospital of Jilin University

cardonilizumab combined with renvastinib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Renal Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News